Lava Therapeutics NV Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
LAVA Therapeutics NV's Chief Financial Officer, Fred M. Powell, disposed of 65,000 common shares and cancelled 124,700 share options as part of a pre-arranged purchase agreement.
LAVA Therapeutics director Mary E. Wadlinger canceled 33,390 share options in exchange for cash and contingent value rights as part of a Purchase Agreement.
LAVA Therapeutics director Christy J. Oliger reported the cancellation of 33,390 share options in exchange for cash and contingent value rights.
LAVA Therapeutics Director James Noble cancels 33,390 share options for cash and contingent value rights.
LAVA Therapeutics Director Peter A. Kiener cancelled 33,390 share options, exchanging them for cash and contingent value rights as part of a pre-arranged plan.
LAVA Therapeutics NV Director Jay T. Backstrom cancelled 33,390 share options in exchange for cash and contingent value rights as part of a purchase agreement.
LAVA Therapeutics Director Karen J Wilson disposed of 10,000 common shares and 33,390 share options as part of a pre-arranged purchase agreement with XOMA Royalty Corporation.
LAVA Therapeutics NV Director Kapil Dhingra disposed of 30,000 common shares and 33,390 share options as part of a Purchase Agreement.
LAVA Therapeutics CEO Stephen A. Hurly disposed of 5,000 common shares and cancelled 335,100 share options under a pre-planned agreement.
Gilde Healthcare, a 10% owner of LAVA Therapeutics NV, reported significant sales of common shares totaling over 2.8 million shares in October 2025.
Cooperatieve Gilde Healthcare IV U.A., a 10% owner and director of LAVA Therapeutics NV, reported the sale of 475,027 common shares over three days in October 2025.
Gilde Healthcare, a 10% owner and director of LAVA Therapeutics NV, reported multiple sales of common shares in early October 2025.
Versant Venture Capital VI and affiliated entities have fully divested their holdings in LAVA Therapeutics NV, selling over 2.9 million shares at a weighted average price of $1.4014.
Versant Venture Capital VI, L.P. and its affiliates reported the sale of over 1.6 million shares of LAVA Therapeutics NV common stock across three days in September 2025.
Karen J. Wilson, a director of LAVA Therapeutics N.V., acquired options to purchase 33,390 common shares at $0.93 per share, according to a recent SEC Form 4 filing.
Mary E. Wadlinger, a director of LAVA Therapeutics N.V., reports the acquisition of options to purchase 33,390 common shares at $0.93 per share in a recent SEC filing.
Director James Noble acquired options to purchase 33,390 common shares of Lava Therapeutics at $0.93 per share.
Director Peter Kiener reports acquisition of options to purchase 33,390 common shares of LAVA Therapeutics NV.
Director Jay T. Backstrom acquires options to purchase 33,390 common shares of LAVA Therapeutics NV at $0.93 per share.
Kapil Dhingra, a director of LAVA Therapeutics NV, acquired options to purchase 33,390 common shares at $0.93 per share on February 13, 2025.
Fred M. Powell, CFO of LAVA Therapeutics N.V., reports the acquisition of stock options.
Charles Q. Morris, Chief Medical Officer of LAVA Therapeutics NV, reports the acquisition of share options.
Director Christy J. Oliger acquired options to purchase 33,390 common shares of LAVA Therapeutics NV on February 13, 2025.
CEO Stephen A. Hurly of LAVA Therapeutics NV was granted options to purchase 335,100 common shares on February 13, 2025, vesting monthly over four years.